The company has signed technology deals with Repertoire Genesis of Japan, Stratifyer Molecular Pathology of Germany, and the University of Bonn.
Newly appointed interim CEO Thierry Bernard attempted to assuage investors' fears in the wake of a tumultuous month for Qiagen.
The lowered guidance is due to continued expected weakness in China, exacerbated by the company's decision to halt the development of new next-generation sequencing instruments.
Illumina officials discussed several issues with investors, including the new Qiagen partnership, while at ASHG the firm introduced reagent kit upgrades.
The agreement enables NeuMoDx to bring sample-to-result HPV screening to customers in Europe, where its systems are distributed by Qiagen.
Qiagen will have an undisclosed number of layoffs as a result of the halted GeneReader development, though it plans to create new jobs elsewhere.
Qiagen will develop IVDs for use on Illumina's clinical sequencers and reported preliminary Q3 revenue growth of 3 percent at a constant exchange rate.
Columbia and Qiagen filed a suit against Illumina in federal court today, alleging infringement of two patents that were issued today.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
In PLOS this week: Mycobacterium abscessus linked to gastric conditions, placental gene expression changes associated with preterm birth, and more.
The Guardian reports that UK universities are looking into ways to reduce labs' reliance on single-use plastics.
People with certain gene variants tend to not like vegetables, particularly bitter ones, CNN reports.
MIT's Technology Review reports on a company's genetic test that gauges an embryo's susceptibility to certain diseases.